Nephrogenic Systemic Fibrosis

• CLINICAL_TRIALS trial_result · 2019-02-04
  Clinical Trial Update: Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration

  An observational study assessing the incidence of nephrogenic systemic fibrosis in patients with renal impairment after administration of Do…

• CLINICAL_TRIALS withdrawal · 2017-08-02
  Clinical Trial Update: Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection

  A clinical trial evaluating nephrogenic systemic fibrosis in patients with chronic kidney disease following OptiMARK injection has been with…

• CLINICAL_TRIALS trial_result · 2017-05-19
  Clinical Trial Update: Pilot Study of Imatinib Mesylate to Treat Nephrogenic Systemic Fibrosis [Phase 2]

  Phase 2 pilot trial evaluating imatinib mesylate for treating nephrogenic systemic fibrosis; results were posted in 2017.

• CLINICAL_TRIALS trial_result · 2014-12-04
  Clinical Trial Update: Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

  Completed clinical trial analyzing tissue gadolinium levels in patients with nephrogenic systemic fibrosis to explore exposure and potential…

• CLINICAL_TRIALS trial_result · 2014-11-21
  Clinical Trial Update: Plasmapheresis for Nephrogenic Fibrosing Dermopathy (NFD)/Nephrogenic Systemic Fibrosis (NSF) [Phase 4]

  Phase 4 trial investigating plasmapheresis for nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis has been terminated.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS safety_alert · 2014-11-04
  Clinical Trial Update: Evaluation of the Risk of NSF Following MultiHance Injection in Patients With Chronic Kidney Disease

  A completed clinical trial assessing the risk of nephrogenic systemic fibrosis after MultiHance (gadoteridol) administration in patients wit…

• CLINICAL_TRIALS safety_alert · 2014-09-22
  Clinical Trial Update: Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist

  A clinical trial update reports the risk of Nephrogenic Systemic Fibrosis in patients with moderate renal insufficiency following administra…

• CLINICAL_TRIALS trial_result · 2014-05-07
  Clinical Trial Update: Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR

  This completed prospective trial evaluated the incidence of nephrogenic systemic fibrosis in patients with kidney disease undergoing magneti…

• CLINICAL_TRIALS trial_result · 2012-09-18
  Clinical Trial Update: Evaluation of the Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Without Exposure to Gadolinium Based Contrast Agents (GBCA)

  This completed clinical trial evaluated the risk of nephrogenic systemic fibrosis in patients with chronic kidney disease who had no exposur…

• CLINICAL_TRIALS trial_result · 2012-06-22
  Clinical Trial Update: Nephrogenic Systemic Fibrosis With Gadollinum [Phase 2, Phase 3]

  Phase 2/Phase 3 trial investigating Gadollinum for Nephrogenic Systemic Fibrosis in patients with renal failure. The status of the trial is …

• CLINICAL_TRIALS trial_result · 2012-06-05
  Clinical Trial Update: Treatment of Patients With Nephrogenic Systemic Fibrosis With Glivec [Phase 3]

  Phase 3 trial evaluating imatinib (Glivec) for nephrogenic systemic fibrosis has completed.

• CLINICAL_TRIALS research · 2010-12-15
  Clinical Trial Update: Validation of a Questionnaire to Identify Signs and Symptoms of Nephrogenic Systemic Fibrosis

  This completed trial validated a questionnaire designed to identify signs and symptoms of nephrogenic systemic fibrosis, aiming to improve a…

• EMA safety_alert · 2007-02-07
  Public statement: Vasovist and nephrogenic systemic fibrosis (NSF)

  EMA public statement regarding the contrast agent Vasovist and the risk of nephrogenic systemic fibrosis (NSF), highlighting safety conside…